#1 Clinical Trials Search in Europe

Leucine

Leucine, an essential amino acid, is being investigated in various clinical trials for its potential therapeutic effects on a range of conditions. These trials explore leucine’s impact on rare diseases like Diamond Blackfan Anemia and Niemann-Pick Disease Type C, as well as more common conditions such as depression. Researchers are studying how leucine supplementation may improve symptoms, quality of life, and overall health outcomes for patients with these diverse conditions.

Table of Contents

What is Leucine?

Leucine is an essential amino acid, which means our bodies cannot produce it on their own, so we need to get it from our diet or supplements. It’s one of the building blocks of proteins in our body and plays important roles in various bodily functions[1]. Leucine is being studied for its potential therapeutic effects in several medical conditions.

Leucine is also known by its scientific name L-leucine. In some studies, a modified form called N-acetyl-L-leucine (also known as IB1001 or levacetylleucine) is used[5].

Potential Uses of Leucine

Research is ongoing to explore the potential benefits of leucine in various medical conditions. Some of the areas being investigated include:

  • Diamond Blackfan Anemia (DBA): A rare blood disorder affecting red blood cell production[1][2]
  • Major Depression: A common mental health condition characterized by persistent feelings of sadness and loss of interest[3][4]
  • Ataxia-Telangiectasia (A-T): A rare genetic disorder affecting the nervous system, immune system, and other body systems[5]
  • Niemann-Pick Disease Type C (NPC): A rare genetic disorder that affects the body’s ability to transport cholesterol and other fatty substances within cells[6]

Leucine in Diamond Blackfan Anemia

Diamond Blackfan Anemia (DBA) is a rare blood disorder where the bone marrow doesn’t produce enough red blood cells. Researchers are studying leucine as a potential treatment for DBA patients who depend on blood transfusions[1][2].

The hope is that leucine might help increase red blood cell production in these patients. This could potentially reduce the need for frequent blood transfusions or even eliminate the need for them altogether[1].

Leucine in Major Depression

Scientists are exploring whether leucine could help treat major depression, especially in cases where inflammation might be contributing to the condition[3][4].

One study is looking at whether leucine can improve symptoms like loss of pleasure in activities (anhedonia) and slowed movements (psychomotor slowing) in middle-aged adults with depression[4]. Researchers think leucine might help by affecting certain brain chemicals and improving how brain cells communicate.

N-Acetyl-L-Leucine in Ataxia-Telangiectasia

Ataxia-Telangiectasia (A-T) is a rare genetic disorder that affects multiple body systems, including movement and coordination. A modified form of leucine called N-acetyl-L-leucine (IB1001) is being studied as a potential treatment for A-T[5].

Researchers are investigating whether this compound can improve symptoms like difficulty with balance and coordination (ataxia) in people with A-T.

N-Acetyl-L-Leucine in Niemann-Pick Disease Type C

Niemann-Pick Disease Type C (NPC) is a rare genetic disorder that affects the body’s ability to process fats (lipids). N-acetyl-L-leucine is also being studied as a potential treatment for NPC[6].

The research aims to see if this compound can improve symptoms of NPC, particularly those related to movement and coordination.

Dosage and Administration

The dosage and method of taking leucine can vary depending on the specific condition being treated and the form of leucine used. Here are some examples from the ongoing studies:

  • For Diamond Blackfan Anemia: 700 mg/m² taken by mouth three times a day[1]
  • For Major Depression: 4 grams taken by mouth twice daily[3]
  • For Ataxia-Telangiectasia and Niemann-Pick Disease Type C: N-acetyl-L-leucine is given as granules to be mixed with water, orange juice, or almond milk. The dose is usually based on the patient’s weight[5][6]

It’s important to note that these dosages are being used in research studies. If leucine becomes an approved treatment, the recommended dosage might be different.

Potential Side Effects

As with any medical treatment, leucine may cause side effects. The ongoing studies are carefully monitoring participants for any adverse effects[1][3].

In the studies on major depression, researchers are using specific scales to measure the frequency, intensity, and burden of side effects[3]. This helps them understand how well patients tolerate the treatment.

It’s important to remember that leucine is still being researched for these conditions. More studies are needed to fully understand its effectiveness and safety. If you’re interested in leucine for any medical condition, always consult with your healthcare provider first. They can provide the most up-to-date information and advice based on your individual health situation.

Condition Leucine Form Dosage Duration Key Outcomes Measured
Diamond Blackfan Anemia L-leucine 700 mg/m2/dose, 3 times daily 6-9 months Hemoglobin levels, transfusion independence
Major Depressive Disorder L-leucine 4 gm twice daily 2 weeks Depression severity (QIDS-SR score), fatigue, anhedonia
Midlife Depression L-leucine 4.31 g/day 6 weeks Brain glutamate levels, anhedonia, psychomotor function
Ataxia-Telangiectasia N-Acetyl-L-Leucine 2-4 g/day (weight-based) 12 weeks per treatment period Ataxia rating scales, quality of life measures
Niemann-Pick Disease Type C N-Acetyl-L-Leucine 4 g/day for ≥13 years; weight-based for <13 years 12 weeks per treatment period Ataxia rating scales, disability rating, quality of life

FAQ

  • What is leucine and why is it being studied in clinical trials? Leucine is an essential amino acid that plays a crucial role in protein synthesis and various metabolic processes. It's being studied in clinical trials because of its potential to improve symptoms in conditions like Diamond Blackfan Anemia, Niemann-Pick Disease Type C, and depression. Researchers believe leucine may help with red blood cell production, brain function, and mood regulation.
  • How is leucine administered in these clinical trials? In most of the trials, leucine is administered orally. It's often provided as a powder or granules that can be mixed with water, orange juice, or almond milk. The dosage varies depending on the specific trial and condition being studied, but it's typically given multiple times a day.
  • What are some of the conditions being studied with leucine supplementation? The clinical trials are investigating leucine's effects on several conditions, including Diamond Blackfan Anemia (a rare blood disorder), Niemann-Pick Disease Type C (a rare genetic disorder), Ataxia-Telangiectasia (a neurological disorder), and major depressive disorder.
  • How long do these leucine clinical trials typically last? The duration of the trials varies, but many last between 6 to 24 weeks. Some trials have a crossover design where participants receive both leucine and a placebo at different times during the study. There are also some trials with longer follow-up periods or extension phases.
  • What are some of the outcomes being measured in these leucine trials? The trials measure various outcomes depending on the condition being studied. These can include changes in blood cell counts, improvements in neurological symptoms (like ataxia), changes in depression scores, quality of life measures, and assessments of overall clinical improvement. Researchers also monitor for any side effects or adverse events related to leucine supplementation.

Ongoing Clinical Trials on Leucine

  • Study of Intradialytic Parenteral Nutrition for Muscle Protein Production in Patients on Long-term Hemodialysis Treatment

    Not yet recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands

  • Study on Nutrition Methods and Muscle Loss After Esophagectomy Using SmofKabiven and Drug Combination for Patients Recovering from Esophageal Surgery

    Not yet recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Denmark

  • Study on Early vs. Delayed Supplementary Parenteral Nutrition with SmofKabiven for Patients After Major Emergency Abdominal Surgery

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Denmark

Glossary

  • Leucine: An essential amino acid that plays a crucial role in protein synthesis and various metabolic processes in the body.
  • Diamond Blackfan Anemia (DBA): A rare blood disorder characterized by a failure of the bone marrow to produce red blood cells.
  • Niemann-Pick Disease Type C (NPC): A rare genetic disorder that affects the body's ability to metabolize fats (lipids), causing them to accumulate in the brain, liver, and spleen.
  • Ataxia-Telangiectasia (A-T): A rare, neurodegenerative disorder that affects the nervous system, immune system, and other body systems.
  • Major Depressive Disorder (MDD): A mental health condition characterized by persistent feelings of sadness, hopelessness, and loss of interest in activities.
  • Anhedonia: The inability to feel pleasure from activities usually found enjoyable.
  • Placebo: A substance with no active therapeutic effect, used as a control in testing new drugs.
  • Crossover study: A type of clinical trial where participants receive two or more treatments in a specific order, allowing each participant to serve as their own control.
  • Hemoglobin (Hb): A protein in red blood cells that carries oxygen throughout the body.
  • Clinical Global Impression (CGI): A rating scale used by healthcare providers to assess the overall clinical state of a patient.

References

  1. https://clinicaltrials.gov/study/NCT01362595
  2. https://clinicaltrials.gov/study/NCT02386267
  3. https://clinicaltrials.gov/study/NCT03079297
  4. https://clinicaltrials.gov/study/NCT06580145
  5. https://clinicaltrials.eu/trial/study-on-the-effects-of-n-acetyl-l-leucine-for-patients-with-ataxia-telangiectasia/
  6. https://clinicaltrials.eu/trial/study-on-n-acetyl-l-leucine-for-patients-with-niemann-pick-disease-type-c/